• Better patient management
    • A non-invasive faecal biomarker specific for intestinal inflammation to support the differential diagnosis of IBD from IBS.
    • Faecal calprotectin is useful for screening patients for suspected IBD, reducing the number of unnecessary invasive diagnostic procedures.
  • Add flexibility to your laboratory routine
    • Simple, efficient, convenient, and hygienic extraction of stool samples with the ready to use IDS Calprotectin Extraction Device.
    • Extended stool extract stability, enabling specimen extraction and testing scheduling convenient.
  •  Streamlined workflow, rapid results and cost effective
    • Ready to use reagents with up to 28 days on-board storage.
    • Calibrate at 14 days interval with ready to use calibrators. and controls

IDS Calprotectin is a chemiluminescence immunoassay performed on IDS system to quantitate the amount of calprotectin in human stool samples. Results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS).

Calprotectin is first extracted from stool samples using the IDS Calprotectin Extraction Device, prior to loading specimens on the IDS system. 15µL of extracted sample or control are used in the sandwich assay with monoclonal anti-calprotectin antibody and acridinium labelled monoclonal anti-calprotectin.

Inflammatory bowel diseases (IBD) are chronic intestinal disorders caused by several factors, including external influences, intestinal microbiota and genetics. The two major clinically defined types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC).  Patient symptoms are chronic or recurrent episodes of abdominal pain and diarrhea. The clinical manifestations of IBD are not specific and symptoms are similar to other non-organic diseases such as irritable bowel syndrome (IBS), requiring endoscopy to confirm diagnosis.

Measurement of fecal calprotectin, a calcium-binding protein, is useful to screen for intestinal inflammation associated with disease activity, such as at initial presentation or relapse. 1-3 Faecal calprotectin testing is a noninvasive substitute for endoscopy if the procedure is unavailable or unfeasible.2 Faecal calprotectin is considered among the most useful of the inflammatory markers for IBD. Concentrations of faecal calprotectin have been found to correlate well with the level of mucosal inflammation,4 and a normal fecal calprotectin result has a high negative predictive value for IBD.3 The non-invasive measurement of faecal calprotectin is considered a useful screening tool for differentiating IBD from IBS.5-7


  1. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018; 113 (4): 481-517.
  2. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019; 114 (3): 384-413.
  3. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. 2019;68(Suppl 3):s1-s106.
  4. Yu YR, Rodriguez R. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017; 26 (6): 349-355.
  5. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12(6):524-534.
  6. Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369.
  7. Burri E, Beglinger C. Faecal calprotectin in the diagnosis of inflammatory bowel disease. Biochem Med 2011;21(3):245-53.